InvestorsHub Logo
Followers 17
Posts 936
Boards Moderated 0
Alias Born 04/26/2010

Re: Amatuer17 post# 232344

Thursday, 06/28/2018 10:29:20 AM

Thursday, June 28, 2018 10:29:20 AM

Post# of 403047
Oh, look, another falling for AF's selective truths. AF rightfully criticizes Leo for comparing Brilacidin enema to oral medication. Then he goes and compares Brilacidin enema to budesonide foam instead of budesonide enema for which clinical results are also available. One wonders why? Could it be that the best remission rate budesonide enema managed was 27 % . And don't bring up this study. It uses very lax (and specifically not approved by FDA) definition of clinical remission in UP/UPS.

And about that subject baseline not provided by Leo. AF's budesonide foam trial had subjects with mild to moderate UP/UPS. Next step down in severity is healthy.

There is a rule to be followed when reading AF's articles. If AF gets "personal" with management - check what he may be omitting and/or distorting. An Example of AF's reality distortion field in action (Sorry, S.J): AF once called doxorubicin an old and marginal treatment for STS. Old: true. Marginal, with < 20 % response rate: true. At the time of AF's article still the Standard of Care in first line for STS: true and omitted by AF. That omission sort of changed the whole thing. Don't you think?

"I would rather have questions that can't be answered than answers that can't be questioned." Richard P. Feynman

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News